Jpmorgan Chase & CO Axogen, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AXGN
# of Institutions
168Shares Held
40.1MCall Options Held
69.1KPut Options Held
0-
First Light Asset Management, LLC Edina, MN4.53MShares$64.1 Million7.55% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$46 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.73MShares$38.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.51MShares$35.6 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.93MShares$27.3 Million0.03% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $599M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...